Mateos M-V, Dimopoulos MA, Cavo M, Suzuki K, Jakubowiak A, Knop S, Doyen C, Lucio P, Nagy Z, Kaplan P et al..  2018.  Daratumumab plus Bortezomib, Melphalan, and Prednisone for Untreated Myeloma.. N Engl J Med. 378(6):518-528.

Xue Y, Martelotto L, Baslan T, Vides A, Solomon M, Mai TThi, Chaudhary N, Riely GJ, Li BT, Scott K et al..  2017.  An approach to suppress the evolution of resistance in BRAF-mutant cancer.. Nat Med. 23(8):929-937.

Perez K, Clancy TE, Mancias JD, Rosenthal MH, Wolpin BM.  2017.  When, What, and Why of Perioperative Treatment of Potentially Curable Pancreatic Adenocarcinoma.. J Clin Oncol. 35(5):485-489.

Liang LW, Perez AR, Cangemi NA, Zhou Q, Iasonos A, Abu-Rustum N, Alektiar KM, Makker V.  2016.  An Assessment of Prognostic Factors, Adjuvant Treatment, and Outcomes of Stage IA Polyp-Limited Versus Endometrium-Limited Type II Endometrial Carcinoma.. Int J Gynecol Cancer. 26(3):497-504.

Kim D-Y, Joo Y-D, Lim S-N, Kim S-D, Lee J-H, Lee J-H, Kim DHwan Denni, Kim K, Jung CWon, Kim I et al..  2015.  Nilotinib combined with multiagent chemotherapy for newly diagnosed Philadelphia-positive acute lymphoblastic leukemia.. Blood. 126(6):746-56.

Heath JL, Weiss JM, Lavau CP, Wechsler DS.  2014.  Effects of iron depletion on CALM-AF10 leukemias.. Exp Hematol. 42(12):1022-1030.e1.

Steinman J, Ariyan C, Rafferty B, Brady MS.  2014.  Factors associated with response, survival, and limb salvage in patients undergoing isolated limb infusion.. J Surg Oncol. 109(5):405-9.

Halaas JL, Moskowitz CH, Horwitz S, Portlock C, Noy A, Straus D, O'Connor OA, Yahalom J, Zelenetz AD.  2005.  R-CHOP-14 in patients with diffuse large B-cell lymphoma: feasibility and preliminary efficacy.. Leuk Lymphoma. 46(4):541-7.